At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
Chondroitin +1 moredrug
Likely dose
Chondroitin 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pase II Study of Glucosamine With Chondroitin on Joint Symptoms Induced By Aromatase Inhibitors in Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Chondroitin and Glucosamine for Breast Cancer and Joint Pain. Completed, enrolled 53 participants across 1 site.
Detailed Summary
Investigators are hoping to learn if glucosamine with chondroitin can help relieve joint pain/stiffness associated with aromatase inhibitors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Joint Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartOct 2008
Primary CompletionJul 2012
Study CompletionSep 2012
TodayJul 2026
First PostedJun 5, 2008
Enrollment StartOct 1, 2008
Primary CompletionJul 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.1 years ago
Interventions
Chondroitindrug
400mg chondroitin three times a day (TID) for twenty-four weeks
Glucosaminedrug
500mg glucosamine TID for twenty-four weeks